SAUNDERS BRENT L

CEO Brent L. Saunders bought 14,700 shares of BLCO at $17.14 (2026-03-06); 5 other insiders also bought within 14 days

CEO and Chairman Brent L. Saunders purchased 14,700 shares at $17.14, increasing his holdings by 1.5% to 981,275 shares. This transaction is part of a cluster pattern, with 5 other insiders also buying BLCO within the past 14 days. At the company level, context is mixed: Bausch & Lomb reported $1.3B in latest quarterly revenue (+6.5% annual growth) but net income of $-28.0M, indicating the company was unprofitable over its most recent full fiscal year. Saunders' own track record at BLCO is noteworthy—his 2 prior purchases at this ticker returned +4.0% and +4.1% at 30 days and +29.0% and +31.0% at 90 days respectively. The current share price of $17.12 is 8.0% below the 52-week high of $18.60, positioning this buy near the upper range of recent trading.

BLCO CEO Brent Saunders buys 22,000 shares at $11.28; stock now at $11.80 amid company losses

Brent L Saunders, CEO and Chairman, purchased 22,000 shares at $11.28 on 2025-05-22, increasing his holdings by +3.1% to 741.2K shares. The purchase occurs against a backdrop of material headwinds: Bausch & Lomb posted a net loss of $-212.0M in its latest quarter despite $1.1B in revenue, and the stock is trading -43.6% from its 52-week high of $20.93. Saunders' cross-ticker track record shows a 66.67% 90-day win rate on buys (avg 90d return -9.9%), and his prior BLCO buy on 2024-08-05 generated a +31.0% 90-day return—indicating his picks at this company have outperformed his broader pattern. The current purchase at $11.28 is below the 52-week low of $10.90 adjusted for timing, placing it in a depressed zone relative to recent history, though the company's unprofitability leaves material downside risk unresolved.

Director Brent L Saunders sold all 120,000 shares of SPRY at $14.25 ($1.7M), exiting complete position.

SAUNDERS BRENT L, a Director, executed a complete liquidation of his ARS Pharmaceuticals holding, selling all 120,000 shares at $14.25 on 2025-05-20, reducing post-transaction holdings to 0 shares. The sale occurred at a price -17.0% from the 52-week high of $17.49, and the stock is currently trading at $14.52, only 2.0% above the transaction price. His cross-ticker track record shows a 66.67% win rate on prior purchases with an average 90-day return of -9.9%, though these metrics apply to his entire portfolio history rather than SPRY specifically. The company's fundamentals show revenue of $7,973,000.00 in the latest quarter against net income of $-33,940,000.00, with a P/E of 181.50 and market cap of $1,426,060,905.72; the director's complete exit coincides with a company at an early-stage cash-burn profile despite 297063.3% annual revenue growth.

Director Brent L Saunders bought 40,450 SKIN shares at $1.08 on 2024-08-12; stock now -82.3% from 52-week high.

Director Brent L Saunders purchased 40,450 shares at $1.08, a modest increment to his 5.88M share position (0.7% increase), as Beauty Health traded near its 52-week low of $1.12. The company reported $90.6M in latest quarterly revenue with only $202.0K net income and was unprofitable over its most recent full fiscal year, indicating fundamental operational challenges. Saunders' prior buy at this same ticker on 2023-08-16 returned +10.3% in 30 days but -77.2% in 90 days, establishing a pattern of deteriorating performance post-purchase at SKIN. The current stock price of $1.26 is -37.3% below where it traded 30 days ago and -54.5% below where it traded 90 days ago, consistent with the downward momentum observed following his previous SKIN acquisition.

Bausch & Lomb CEO Saunders buys 32,250 shares at $15.66; stock now -21.9% from 52-week high amid company losses

CEO Brent L. Saunders purchased 32,250 shares at $15.66 on 2024-08-05, bringing his total holdings to 627,419 shares, a 5.4% increase in his position. The buy occurs at a price -21.9% below the 52-week high of $19.58, while the company posted net income of $-151,000,000.00 for its most recent full fiscal year. Across his cross-ticker track record, Saunders' prior buys averaged 90-day returns of -77.2% with a 0.00% win rate, indicating a pattern of poorly-timed equity purchases. The purchase warrants observation given the company's ongoing unprofitability despite $1,216,000,000.00 in latest quarterly revenue and 10.0% annual revenue growth.